Extended Data Fig. 8: IC subgroups harbor distinct TMEs.
From: Complex rearrangements fuel ER+ and HER2+ breast tumours
a) Schematic illustrating additional transcriptomic profiles and overlap with genomic profiles induced in Fig. 1a. Created with BioRender.com. b) Mean proportion of different cell types from IMC data by TME subtypes. The Wilcoxon test significance was reported above each comparison as follow: ns: not significant, P ≤ 0.05 (*), P ≤ 0.01 (**), P ≤ 0.001 (***), and P ≤ 0.0001 (****). c) Proportion of TME subtypes in primary and metastatic samples for the ER+ High-risk ICs and IC5 (HER2 + ) by ER status. d) Proportion of TME subtypes for primary samples (METABRIC) in ER+ Typical invasive IDC and ER+ Typical ILC. e) Mean proportion of fibroblasts and T cells in TNBC samples with IMC proteomic data obtained from bootstrapping (n = 1000). f) Proportion of TME subtypes for primary and metastatic samples stratified by ER status. g) Proportion of TME subtypes for primary samples and liver metastases by groups. IMC, imaging mass cytometry; SMA, smooth muscle actin.
